Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT1 | P30419 | 10/20 | 0.44 |
| ▸ | NMT2 | O60551 | 9/20 | 0.44 |
| ▸ | KDM1A | O60341 | 3/20 | 0.42 |
| ▸ | GHSR | Q92847 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | KDM5A | P29375 | 1/20 | 0.39 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31385440 | 0.96 | GHSR (0.41) | NMT1NMT2KDM1AGHSRMEN1 | |
| SCHEMBL9120793 | 0.96 | GHSR (0.41) | NMT1NMT2KDM1AGHSRMEN1 | |
| SCHEMBL29588633 | 0.96 | GHSR (0.41) | NMT1NMT2KDM1AGHSRMEN1 | |
| SCHEMBL30613577 | 0.96 | GHSR (0.41) | NMT1NMT2KDM1AGHSRMEN1 | |
| SCHEMBL30973948 | 0.94 | MEN1 (0.42) | NMT1NMT2KDM1AGHSRMEN1 | |
| SCHEMBL30444128 | 0.94 | NMT1 (0.46) | NMT1NMT2KDM1AMAOBKDM5A | |
| SCHEMBL29517196 | 0.93 | MEN1 (0.40) | NMT1NMT2KDM1AMEN1KMT2A | |
| SCHEMBL29517268 | 0.92 | NMT1 (0.45) | NMT1NMT2KDM1AGHSRMAOB | |
| SCHEMBL29679965 | 0.92 | KDM1A (0.43) | NMT1NMT2KDM1AGHSRMAOB | |
| SCHEMBL29496543 | 0.92 | MEN1 (0.44) | KDM1AGHSRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295259-A1 | Conjugated Hepcidin Mimetics | PROTAGONIST THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-11472842-B2 | Analogues of hepcidin mimetics with improved in vivo half lives | PROTAGONIST THERAPEUTICS, INC. (US) | 2022-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11472842-B2 | Analogues of hepcidin mimetics with improved in vivo half lives | HAMP, VIP, HDGF | NMT1 508/4885NMT2 546/4885KDM1A 4309/4885 |
| US-20230295259-A1 | Conjugated Hepcidin Mimetics | HAMP, VIP, HDGF | NMT1 439/4885NMT2 533/4885KDM1A 4143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.